Printer Friendly

Celyad target lowered to $48 on new launch timeline at H.C. Wainwright.

H.C. Wainwright analyst Edward White lowered his price target for Celyad to $48 from $52 after Celyad presented updates on CYAD-01 and CYAD-101. Both studies showed disease control with patients exhibiting partial response and stable disease, White tells investors in a research note. And importantly, both therapies were well tolerated as there were no reports of cytokine syndrome release Grade 2 or higher, and no serious adverse events, dose-limiting toxicities nor on-target off-tumor toxicity, adds the analyst. The analyst trimmed his price target after moving back his launch expectation for CYAD-01 to 2024. White keeps a Buy rating on the shares.

COPYRIGHT 2019 The Fly
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2019 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:The Fly
Article Type:Chronology
Date:Jul 5, 2019
Previous Article:Judy Shelton, one of President Trump's Fed nominee, said the pro-growth agenda.
Next Article:On The Fly: ETF fund flow highlights.

Terms of use | Privacy policy | Copyright © 2022 Farlex, Inc. | Feedback | For webmasters |